Pemphigus
Authors:
- 24 November 2008
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (12) , 1478-1496
Abstract
Pemphigus refers to a group of potentially life‐threatening autoimmune diseases of the skin and mucous membranes, characterized by the formation of blisters and erosions of the skin. An autoimmune process, directed against keratinocyte desmosomal cadherins, interferes with the adhesive function of these molecules. This results in the separation of keratinocytes and clinical manifestation of blistering. Differences in the particular antigens targeted by the antibodies and in the distribution of these antigens in the different regions of the body and in the separate layers of the epidermis result in different clinical manifestations of the disease. Diagnosis of pemphigus is based on three independent groups of criteria: clinical features (flaccid blisters and erosions on skin and oral mucosa), histologic findings (epidermal acantholysis) and immunological tests (circulating and skin‐fixed antibodies against keratinocyte surface antigens). The principle aim of treatment is to reduce inflammatory response and autoantibody production, thereby achieving disease remission. Systemic corticosteroids are still the most useful drugs in the treatment of pemphigus and continue to be the mainstay of therapy for this disease. Adjuvant drugs, such as immunosuppressants, are commonly used in combination, in order to increase efficacy and have a steroid‐sparing effect, thereby allowing reduced maintenance doses and less side effects of systemic corticosteroids. Other options include intravenous immunoglobulin and plasmapheresis. However, more research is needed to develop treatments with the least possible toxicity.Keywords
This publication has 162 references indexed in Scilit:
- Management of autoimmune bullous diseases: Pharmacology and therapeuticsJournal of the American Academy of Dermatology, 2004
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporineJournal of the American Academy of Dermatology, 1997
- Circulating pemphigus IgG in families of patients with pemphigus: Comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblottingJournal of the American Academy of Dermatology, 1997
- The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: Preliminary studyJournal of the American Academy of Dermatology, 1994
- Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 casesJournal of the American Academy of Dermatology, 1993
- Effects of intravenous γ-globulin in pemphigusJournal of the American Academy of Dermatology, 1990
- Effect of plasmapheresis therapy on circulating levels of pemphigus antibodiesJournal of the American Academy of Dermatology, 1990
- Treatment of nine cases of pemphigus vulgaris with cyclosporineJournal of the American Academy of Dermatology, 1988
- Use of cyclophosphamide in azathioprine failures in pemphigusJournal of the American Academy of Dermatology, 1987